US5770396A
(en)
*
|
1992-04-16 |
1998-06-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Isolation characterization, and use of the human beta subunit of the high affinity receptor for immunoglobulin E
|
EP0589840B1
(de)
*
|
1992-09-24 |
2004-04-14 |
Novartis AG |
Umgestaltete monoklonale Antikörper gegen ein Immunglobulinisotyp
|
US5958708A
(en)
*
|
1992-09-25 |
1999-09-28 |
Novartis Corporation |
Reshaped monoclonal antibodies against an immunoglobulin isotype
|
US6066718A
(en)
*
|
1992-09-25 |
2000-05-23 |
Novartis Corporation |
Reshaped monoclonal antibodies against an immunoglobulin isotype
|
US5914110A
(en)
*
|
1993-09-07 |
1999-06-22 |
Smithkline Beecham Corporation |
Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
US5928904A
(en)
*
|
1993-09-07 |
1999-07-27 |
Smithkline Beecham Corporation |
DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
US20020193575A1
(en)
|
1993-09-07 |
2002-12-19 |
Smithkline Beecham P.L.C. |
Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
GB9324013D0
(en)
*
|
1993-11-22 |
1994-01-12 |
3I Res Expl Ltd |
Polypeptides
|
AP660A
(en)
*
|
1994-01-18 |
1998-08-18 |
Genentech Inc |
A method of treatment of parasitic infection using IgE antagonists.
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
US20040197326A1
(en)
*
|
1995-07-27 |
2004-10-07 |
Genentech, Inc. |
Method for treatment of allergic asthma
|
KR100584051B1
(ko)
*
|
1996-03-01 |
2006-05-30 |
노파르티스 아게 |
알레르기에 대한 백신 접종 및 치료를 위한 펩티드임뮤노겐
|
US5958880A
(en)
*
|
1996-12-19 |
1999-09-28 |
Heska Corporation |
Feline Fc epsilon receptor alpha chain proteins and therapeutic uses thereof
|
US7122636B1
(en)
|
1997-02-21 |
2006-10-17 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and uses of same
|
US5994511A
(en)
*
|
1997-07-02 |
1999-11-30 |
Genentech, Inc. |
Anti-IgE antibodies and methods of improving polypeptides
|
US6172213B1
(en)
|
1997-07-02 |
2001-01-09 |
Genentech, Inc. |
Anti-IgE antibodies and method of improving polypeptides
|
US6057127A
(en)
|
1998-01-29 |
2000-05-02 |
Heska Corporation |
Equine Fc epsilon receptor alpha chain nucleic acid molecules and uses thereof
|
US6504013B1
(en)
*
|
2000-02-01 |
2003-01-07 |
Idexx Laboratories, Inc. |
Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody
|
US7393529B2
(en)
*
|
1998-04-09 |
2008-07-01 |
Idexx Laboratories, Inc. |
Methods and compositions for inhibiting binding of IgE to a high affinity receptor
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
US6299875B1
(en)
*
|
1998-06-04 |
2001-10-09 |
Panacea Pharmaceuticals, Llc |
Methods to block IGE binding to cell surface receptors of mast cells
|
TWI227241B
(en)
*
|
1998-06-20 |
2005-02-01 |
United Biomedical Inc |
IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
|
TR200102493T2
(tr)
*
|
1999-02-25 |
2002-02-21 |
Smithkline Beecham Biologicals S.A. |
IgE'nin C-epsilon-3 veya C-epsilon-4 alanlarından türetilmiş epitoplar veya mimotoplar.
|
US6889145B1
(en)
|
2000-03-15 |
2005-05-03 |
Northwestern University |
Three-dimensional model of a Fc region of an IgE antibody and uses thereof
|
DE60139944D1
(de)
|
2000-10-12 |
2009-10-29 |
Genentech Inc |
Niederviskose konzentrierte proteinformulierungen
|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
ATE417858T1
(de)
|
2002-02-05 |
2009-01-15 |
Genentech Inc |
Proteinaufreinigung
|
JP4319979B2
(ja)
|
2002-04-26 |
2009-08-26 |
ジェネンテック・インコーポレーテッド |
タンパク質の非アフィニティ精製
|
US7365168B2
(en)
|
2002-10-15 |
2008-04-29 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US20060034845A1
(en)
|
2002-11-08 |
2006-02-16 |
Karen Silence |
Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
|
US9320792B2
(en)
|
2002-11-08 |
2016-04-26 |
Ablynx N.V. |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
CA2505325C
(en)
|
2002-11-08 |
2014-02-25 |
Ablynx N.V. |
Stabilized single domain antibodies
|
EP1558650A2
(de)
|
2002-11-08 |
2005-08-03 |
Ablynx N.V. |
Antikörper aus camelidae gegen immunoglobulin e und ihre verwendung zur behandlung allergischer erkrankungen
|
PT1610820E
(pt)
|
2003-04-04 |
2010-12-16 |
Novartis Ag |
Formulações de elevada concentração de anticorpos e proteínas
|
WO2005016968A2
(en)
|
2003-07-28 |
2005-02-24 |
Genentech, Inc. |
Reducing protein a leaching during protein a affinity chromatography
|
CA2545539A1
(en)
|
2003-10-15 |
2005-04-28 |
Pdl Biopharma, Inc. |
Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
|
US7662926B2
(en)
|
2004-09-02 |
2010-02-16 |
Genentech, Inc. |
Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
|
US7655229B2
(en)
|
2004-09-02 |
2010-02-02 |
Chan Andrew C |
Anti-FC-gamma RIIB receptor antibody and uses therefor
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
TWI391399B
(zh)
|
2005-05-25 |
2013-04-01 |
Hoffmann La Roche |
測定溶離多肽之鹽濃度之方法
|
WO2007032804A2
(en)
|
2005-06-30 |
2007-03-22 |
Clifford Risk |
Novel uses for anti-ige therapy
|
FR2902799B1
(fr)
|
2006-06-27 |
2012-10-26 |
Millipore Corp |
Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
|
US8569464B2
(en)
|
2006-12-21 |
2013-10-29 |
Emd Millipore Corporation |
Purification of proteins
|
US8362217B2
(en)
|
2006-12-21 |
2013-01-29 |
Emd Millipore Corporation |
Purification of proteins
|
US8163886B2
(en)
|
2006-12-21 |
2012-04-24 |
Emd Millipore Corporation |
Purification of proteins
|
AU2008209404B2
(en)
|
2007-01-22 |
2012-08-16 |
Genentech, Inc. |
Polyelectrolyte precipitation and purification of antibodies
|
AR065368A1
(es)
|
2007-02-15 |
2009-06-03 |
Astrazeneca Ab |
Anticuerpos para moleculas de ige
|
AU2008275229B2
(en)
|
2007-07-09 |
2014-11-06 |
Genentech, Inc. |
Prevention of disulfide bond reduction during recombinant production of polypeptides
|
PE20140196A1
(es)
|
2007-08-09 |
2014-03-19 |
Boehringer Ingelheim Int |
Anticuerpos anti-cd37
|
AU2008289857B2
(en)
*
|
2007-08-23 |
2014-06-05 |
Phc Corporation |
Use of non-specific reaction inhibitor
|
CA2703279C
(en)
|
2007-10-30 |
2014-04-22 |
Genentech, Inc. |
Antibody purification by cation exchange chromatography
|
WO2009151514A1
(en)
|
2008-06-11 |
2009-12-17 |
Millipore Corporation |
Stirred tank bioreactor
|
DK2848625T3
(da)
|
2008-08-14 |
2019-10-07 |
Genentech Inc |
Fremgangsmåder til fjernelse af en kontaminant under anvendelse af ion bytningsmembrankromatografi med forskydning af naturligt forekommende proteiner
|
EP2684570A1
(de)
|
2008-09-10 |
2014-01-15 |
F. Hoffmann-La Roche AG |
Zusammensetzungen und Verfahren zur Prävention des oxidativen Abbaus von Proteinen
|
WO2010074953A1
(en)
|
2008-12-16 |
2010-07-01 |
Millipore Corporation |
Stirred tank reactor and method
|
US20110020327A1
(en)
|
2008-12-16 |
2011-01-27 |
Millipore Corporation |
Purification of proteins
|
ES2547712T3
(es)
|
2009-02-27 |
2015-10-08 |
Genentech, Inc. |
Métodos y composiciones para el marcado de proteínas
|
SG174258A1
(en)
|
2009-03-06 |
2011-10-28 |
Genentech Inc |
Antibody formulation
|
RU2639288C2
(ru)
|
2009-08-11 |
2017-12-20 |
Дженентек, Инк. |
Получение белков в культуральных средах без глутамина
|
EP3736338A1
(de)
|
2009-09-01 |
2020-11-11 |
F. Hoffmann-La Roche AG |
Verbesserte proteinreinigung durch eine modifizierte protein-a-elution
|
KR20180000342A
(ko)
|
2010-03-22 |
2018-01-02 |
제넨테크, 인크. |
단백질-함유 제제의 안정화에 유용한 조성물 및 방법
|
BR112012027828A2
(pt)
|
2010-05-03 |
2016-08-09 |
Genentech Inc |
composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
|
US8691918B2
(en)
|
2010-05-17 |
2014-04-08 |
Emd Millipore Corporation |
Stimulus responsive polymers for the purification of biomolecules
|
PL2576580T3
(pl)
|
2010-05-28 |
2017-03-31 |
F.Hoffmann-La Roche Ag |
Zmniejszenie poziomu mleczanu i zwiększenie wytwarzania polipeptydu przez obniżenie poziomu ekspresji dehydrogenazy mleczanowej i kinazy dehydrogenazy pirogronianowej
|
SI3586826T1
(sl)
|
2010-06-24 |
2021-09-30 |
F. Hoffmann-La Roche Ag |
Sestavki in postopki za stabilizacijo formulacij, ki vsebujejo beljakovine
|
CN104474546A
(zh)
|
2010-08-13 |
2015-04-01 |
弗·哈夫曼-拉罗切有限公司 |
用于疾病治疗的针对IL-1β和IL-18的抗体
|
WO2012030512A1
(en)
|
2010-09-03 |
2012-03-08 |
Percivia Llc. |
Flow-through protein purification process
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
EP2732021B1
(de)
|
2011-07-08 |
2020-05-27 |
EMD Millipore Corporation |
Verbesserte tiefenfilter für biotechnologische einwegverfahren
|
US20140359902A1
(en)
|
2011-12-16 |
2014-12-04 |
Synthon Biopharmaceuticals B.V. |
EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
|
MY172426A
(en)
|
2011-12-22 |
2019-11-25 |
Genentech Inc |
Ion exchange membrane chromatography
|
AU2013240280A1
(en)
|
2012-03-27 |
2014-10-16 |
Genentech, Inc. |
Improved harvest operations for recombinant proteins
|
EP2849723B1
(de)
|
2012-05-18 |
2018-05-02 |
Genentech, Inc. |
Hochkonzentrierte monoklonale antikörperformulierungen
|
GB2503883A
(en)
*
|
2012-07-09 |
2014-01-15 |
King S College London |
Variant IgE with reduced affinity to CD23
|
EP2934602B1
(de)
|
2012-12-19 |
2019-02-27 |
Genentech, Inc. |
Verfahren und zusammensetzungen zur radiohalogen proteinmarkierung
|
ES2825574T3
(es)
|
2014-07-09 |
2021-05-17 |
Hoffmann La Roche |
Ajuste del pH para mejorar la recuperación por descongelación de bancos de células
|
MX2018011834A
(es)
|
2016-03-29 |
2019-03-06 |
Geltor Inc |
Expresión de proteínas en bacterias gram negativas en la que la relación del volumen periplasmático con respecto al volumen citoplasmático está entre 0.5:1 y 10:1.
|
GB201610198D0
(en)
|
2016-06-10 |
2016-07-27 |
Ucb Biopharma Sprl |
Anti-ige antibodies
|
CA3044686A1
(en)
|
2016-12-22 |
2018-06-28 |
Genentech, Inc. |
Methods and formulations for reducing reconstitution time of lyophilized polypeptides
|
JP7128191B2
(ja)
*
|
2017-01-06 |
2022-08-30 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
治療抗IgE抗体並びにその方法及び組成物
|
US20200199525A1
(en)
|
2017-06-08 |
2020-06-25 |
Polpharma Biologics S.A. |
Improved Methods of Cell Culture
|
US11180541B2
(en)
|
2017-09-28 |
2021-11-23 |
Geltor, Inc. |
Recombinant collagen and elastin molecules and uses thereof
|
RU2020113059A
(ru)
|
2017-11-07 |
2021-12-08 |
Хьюбит Дженомикс,Инк. |
Способ первичного предотвращения аллергических заболеваний у детей младенческого возраста с помощью специфичной иммуносупрессии иммуноглобулинов класса ige
|
AU2019299358A1
(en)
|
2018-07-03 |
2021-02-18 |
Bristol-Myers Squibb Company |
Methods of producing recombinant proteins
|
MA53859A
(fr)
|
2018-10-10 |
2022-01-19 |
Boehringer Ingelheim Int |
Procédé de transfert de gaz de membrane dans une culture de bioréacteur à haute densité
|
CN113660953A
(zh)
|
2019-04-01 |
2021-11-16 |
豪夫迈·罗氏有限公司 |
用于稳定含蛋白质制剂的组合物和方法
|
SG11202111349QA
(en)
|
2019-04-12 |
2021-11-29 |
Geltor Inc |
Recombinant elastin and production thereof
|
KR20220039777A
(ko)
|
2019-08-01 |
2022-03-29 |
브리스톨-마이어스 스큅 컴퍼니 |
유가식 세포 배양에서 단백질 생산성을 개선시키는 방법
|
TW202214703A
(zh)
|
2020-07-10 |
2022-04-16 |
大陸商上海濟煜醫藥科技有限公司 |
一種抗IgE的工程化抗體及其應用
|
EP4217383A1
(de)
|
2020-09-22 |
2023-08-02 |
Bristol-Myers Squibb Company |
Verfahren zur herstellung therapeutischer proteine
|
WO2023015234A1
(en)
|
2021-08-05 |
2023-02-09 |
Bristol-Myers Squibb Company |
Cell culture methods for producing therapeutic proteins
|
WO2023049687A1
(en)
|
2021-09-21 |
2023-03-30 |
Bristol-Myers Squibb Company |
Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
|